Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca reported positive interim Phase III data from the VOLGA trial showing that perioperative Imfinzi combined with neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer compared with surgery-based standard care. A second VOLGA regimen combining Imfinzi, Imjudo and enfortumab vedotin also met its event-free survival endpoint and showed a favourable overall survival trend, reinforcing AstraZeneca’s push to establish Imfinzi as an immunotherapy backbone in early-stage bladder cancer and potentially expanding its leadership in high unmet-need uro-oncology segments.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £18000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong underlying fundamentals (profitability, margins, and returns) and a constructive earnings update with reiterated guidance and meaningful pipeline progress. These positives are partly offset by weak technical momentum, moderate valuation, and near-term cash/debt pressures tied to higher investment and payments.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company with a strong focus on oncology and immuno-oncology, developing targeted therapies and immunotherapies for a range of solid tumours. Its cancer portfolio is anchored by checkpoint inhibitors such as Imfinzi and Imjudo, which are already standards of care in multiple lung, liver, biliary tract and gastric cancer indications.
Average Trading Volume: 2,619,073
Technical Sentiment Signal: Buy
Current Market Cap: £213.2B
For a thorough assessment of AZN stock, go to TipRanks’ Stock Analysis page.